How JNJ (Johnson & Johnson) Makes Money in 2026: A Deep-Dive With Income Statement

Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io

Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.

Understanding how a healthcare giant like Johnson & Johnson makes money is essential for investors and anyone interested in the business of pharmaceuticals and medical devices. In this post, we break down Johnson & Johnson's quarterly income statement (Q4 2025) using a Sankey chart to visualize the financial flows — what comes in, where it goes, and what's left as profit.

Quick Johnson & Johnson Overview

Johnson & Johnson operates as a diversified healthcare company with three main segments: Innovative Medicine, MedTech, and Consumer Health. Revenue comes primarily from pharmaceutical sales in Innovative Medicine and medical device sales in MedTech. Consumer Health revenue was reported at $0.0B in Q4 2025, reflecting its divestiture completed prior to the period.

Revenue Breakdown

• Total Revenue (Q4 2025): $24.6B (+9.1% YoY)
  • Innovative Medicine: $15.8B (64.2% of total, +10.0% YoY)
  • MedTech: $8.8B (35.8% of total, +7.5% YoY)
  • Growth is powered by strong demand in oncology and immunology drugs within Innovative Medicine, alongside procedure-based growth in MedTech.

Gross Profit and Margins

• Gross Profit: $21.2B (86.4% gross margin)
  • Cost of Revenue: $3.3B (+-53.0% YoY)
  • Johnson & Johnson maintains robust margins due to its asset-light pharmaceutical model, high pricing power on patented drugs, and manufacturing efficiencies in MedTech.
• Most costs come from manufacturing and raw materials for pharmaceuticals and devices.

Operating Income and Expenses

• Operating Income: $5.4B (+40.4% YoY, 21.9% margin)
• Operating Expenses: $15.8B (+37.0% YoY)
  • R&D: $4.3B (+-19.7% YoY, 17.3% of revenue) — focused on pipeline advancement in oncology, immunology, and neuroscience
  • SG&A: $7.0B (+11.2% YoY, 28.3% of revenue) — covering sales force expansion, marketing for key products, and administrative overhead
  • Johnson & Johnson continues to prioritize innovation while maintaining efficiency through cost controls in non-core areas.

Net Income

• Pre-Tax Income: $5.0B (+27.8% YoY, 20.2% margin)
• Income Tax: Not specified
• Net Income: $5.1B (+49.1% YoY, 20.8% net margin)
• Johnson & Johnson converts a high portion of sales into profit due to scalability of its drug portfolio, pricing power, and operational leverage.

Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.

Want to see what we'll uncover next - before everyone else does?

Find Hidden Gems First!

What Drives Johnson & Johnson's Money Machine?

• Innovative Medicine: 64.2%+ of revenue / powered by blockbuster drugs like Darzalex and Stelara, with oncology and immunology leading growth
• MedTech procedure growth: 7.5% YoY expansion driven by orthopedics, vision, and interventional solutions
• R&D investments: $4.3B allocated to late-stage trials and acquisitions to sustain the Innovative Medicine pipeline
• Future growth areas: Emerging therapies in cardiovascular and neuroscience, though not yet profitable at scale

Visualizing Johnson & Johnson's Financial Flows

The Sankey chart below visualizes how each dollar flows from gross revenue, through costs and expenses, down to net income. This helps investors spot where value is created, what areas weigh on profits, and how efficiently the company operates.

• Most revenue flows into gross profit, with operating expenses (especially SG&A) taking the largest chunk.
• Even after significant R&D investments, 20.8% of revenue drops to the bottom line.

Key Takeaways

• Johnson & Johnson's money comes overwhelmingly from Innovative Medicine pharmaceuticals
• High gross and net margins illustrate the power of Johnson & Johnson's patent-protected drug portfolio
• Heavy investment in R&D, balanced by efficiency in operating costs
• Ongoing growth is driven by pipeline advancements and MedTech volume growth

Explore More Investment Opportunities

For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:

📌 50 Undervalued Stocks (Best overall value plays for 2026)

📌 50 Undervalued Dividend Stocks (For income-focused investors)

📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)

🔍 Check out these stocks on the Value Sense platform for free!

FAQ About Johnson & Johnson's Income Statement

1. What is the main source of Johnson & Johnson's revenue in 2025?

Johnson & Johnson generates over 64% of its revenue from Innovative Medicine. MedTech contributes the remaining 36%, with Consumer Health at $0 post-divestiture.

2. How profitable is Johnson & Johnson in Q4 2025?

Johnson & Johnson reported net income of $5.1B in Q4 2025, with a net margin of approximately 20.8%, reflecting strong profitability driven by high gross margins and operating leverage.

3. What are the largest expense categories for Johnson & Johnson?

The biggest expenses on Johnson & Johnson's income statement are operating expenses, particularly Research & Development (R&D) and Sales, General & Administrative (SG&A) costs. R&D investment reached $4.3B in Q4 2025, as Johnson & Johnson prioritizes pipeline development in oncology and immunology.

4. Why does Consumer Health operate at a loss?

Consumer Health, despite generating $0.0B in revenue, is no longer a reporting segment in Q4 2025. This is because Johnson & Johnson completed its divestiture, aggressively investing resources into higher-margin Innovative Medicine and MedTech—even if legacy operations were unprofitable today.

5. How does Johnson & Johnson's effective tax rate compare to previous years?

Johnson & Johnson's effective tax rate in Q4 2025 was not specified, [consistent with/higher than/lower than] previous years. This [low/high/moderate] rate is primarily due to international operations and tax structuring.